APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Long-Term Asthma Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Long-Term Asthma Drugs Market Outlook and Growth Opportunities 2026

Report ID 174008910431 December 2025198 pages

Choose your research edition.

Industry ResearchLong-Term Asthma Drugs Industry Research Report 2026114 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-Term Asthma Drugs Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Long-Term Asthma Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-Term Asthma Drugs Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-Term Asthma Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Long-Term Asthma Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Long-Term Asthma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Long-Term Asthma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Long-Term Asthma Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Long-Term Asthma Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Long-Term Asthma Drugs market include Novartis, Merck, Roche, Pfizer, GlaxoSmithKline, AstraZeneca, Vectura Group, Teva Pharmaceutical and Boehringer Ingelheim, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Long-Term Asthma Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Long-Term Asthma Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Long-Term Asthma Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Long-Term Asthma Drugs market.

Long-Term Asthma Drugs Segment by Company

Novartis

Merck

Roche

Pfizer

GlaxoSmithKline

AstraZeneca

Vectura Group

Teva Pharmaceutical

Boehringer Ingelheim

Long-Term Asthma Drugs Segment by Type

Tablet

Spray

Long-Term Asthma Drugs Segment by Application

Retail Pharmacy

Online Pharmacy

Hospital Pharmacy

Long-Term Asthma Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Long-Term Asthma Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Long-Term Asthma Drugs key companies, revenue, market share, and recent developments.

3. To split the Long-Term Asthma Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Long-Term Asthma Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Long-Term Asthma Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Long-Term Asthma Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-Term Asthma Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-Term Asthma Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-Term Asthma Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Long-Term Asthma Drugs industry.

Chapter 3: Detailed analysis of Long-Term Asthma Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Long-Term Asthma Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Long-Term Asthma Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Long-Term Asthma Drugs Industry Trends Table 2. Long-Term Asthma Drugs Industry Drivers Table 3. Long-Term Asthma Drugs Industry Opportunities and Challenges Table 4. Long-Term Asthma Drugs Industry Restraints Table 5. Global Long-Term Asthma Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Long-Term Asthma Drugs Revenue Share by Company (2021-2026) Table 7. Global Long-Term Asthma Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Long-Term Asthma Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Long-Term Asthma Drugs Company, Product Type & Application Table 10. Global Long-Term Asthma Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Long-Term Asthma Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Tablet Table 15. Significant Companies of Spray Table 16. Global Long-Term Asthma Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Long-Term Asthma Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Long-Term Asthma Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Long-Term Asthma Drugs Sales Value Share by Type (2021-2026) Table 20. Global Long-Term Asthma Drugs Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Retail Pharmacy Table 22. Significant Companies of Online Pharmacy Table 23. Significant Companies of Hospital Pharmacy Table 24. Global Long-Term Asthma Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Long-Term Asthma Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Long-Term Asthma Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Long-Term Asthma Drugs Sales Value Share by Application (2021-2026) Table 28. Global Long-Term Asthma Drugs Sales Value Share by Application (2027-2032) Table 29. Global Long-Term Asthma Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Long-Term Asthma Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Long-Term Asthma Drugs Sales Value Share by Region (2021-2026) Table 32. Global Long-Term Asthma Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Long-Term Asthma Drugs Sales Value Share by Region (2027-2032) Table 34. Global Long-Term Asthma Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Long-Term Asthma Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Long-Term Asthma Drugs Sales Value Market Share by Country (2021-2026) Table 37. Global Long-Term Asthma Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Long-Term Asthma Drugs Sales Value Market Share by Country (2027-2032) Table 39. Novartis Company Information Table 40. Novartis Business Overview Table 41. Novartis Long-Term Asthma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Novartis Long-Term Asthma Drugs Product Portfolio Table 43. Novartis Recent Development Table 44. Merck Company Information Table 45. Merck Business Overview Table 46. Merck Long-Term Asthma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Merck Long-Term Asthma Drugs Product Portfolio Table 48. Merck Recent Development Table 49. Roche Company Information Table 50. Roche Business Overview Table 51. Roche Long-Term Asthma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Roche Long-Term Asthma Drugs Product Portfolio Table 53. Roche Recent Development Table 54. Pfizer Company Information Table 55. Pfizer Business Overview Table 56. Pfizer Long-Term Asthma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Pfizer Long-Term Asthma Drugs Product Portfolio Table 58. Pfizer Recent Development Table 59. GlaxoSmithKline Company Information Table 60. GlaxoSmithKline Business Overview Table 61. GlaxoSmithKline Long-Term Asthma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. GlaxoSmithKline Long-Term Asthma Drugs Product Portfolio Table 63. GlaxoSmithKline Recent Development Table 64. AstraZeneca Company Information Table 65. AstraZeneca Business Overview Table 66. AstraZeneca Long-Term Asthma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. AstraZeneca Long-Term Asthma Drugs Product Portfolio Table 68. AstraZeneca Recent Development Table 69. Vectura Group Company Information Table 70. Vectura Group Business Overview Table 71. Vectura Group Long-Term Asthma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Vectura Group Long-Term Asthma Drugs Product Portfolio Table 73. Vectura Group Recent Development Table 74. Teva Pharmaceutical Company Information Table 75. Teva Pharmaceutical Business Overview Table 76. Teva Pharmaceutical Long-Term Asthma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Teva Pharmaceutical Long-Term Asthma Drugs Product Portfolio Table 78. Teva Pharmaceutical Recent Development Table 79. Boehringer Ingelheim Company Information Table 80. Boehringer Ingelheim Business Overview Table 81. Boehringer Ingelheim Long-Term Asthma Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Boehringer Ingelheim Long-Term Asthma Drugs Product Portfolio Table 83. Boehringer Ingelheim Recent Development Table 84. Research Programs/Design for This Report Table 85. Authors List of This Report Table 86. Secondary Sources Table 87. Primary Sources List of Figures Figure 1. Long-Term Asthma Drugs Product Image Figure 2. Global Long-Term Asthma Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Long-Term Asthma Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Long-Term Asthma Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Tablet Image Figure 8. Spray Image Figure 9. Global Long-Term Asthma Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Long-Term Asthma Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Long-Term Asthma Drugs Sales Value Share by Type (2021-2032) Figure 12. Retail Pharmacy Image Figure 13. Online Pharmacy Image Figure 14. Hospital Pharmacy Image Figure 15. Global Long-Term Asthma Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Long-Term Asthma Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Long-Term Asthma Drugs Sales Value Share by Application (2021-2032) Figure 18. Global Long-Term Asthma Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Long-Term Asthma Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Long-Term Asthma Drugs Sales Value (2021-2032) & (US$ Million) Figure 21. North America Long-Term Asthma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Long-Term Asthma Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Long-Term Asthma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Long-Term Asthma Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Long-Term Asthma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Long-Term Asthma Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. South America Long-Term Asthma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Long-Term Asthma Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Long-Term Asthma Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Tablet
  • Spray
Applications
  • Retail Pharmacy
  • Online Pharmacy
  • Hospital Pharmacy
Companies covered
  • Novartis
  • Merck
  • Roche
  • Pfizer
  • GlaxoSmithKline
  • AstraZeneca
  • Vectura Group
  • Teva Pharmaceutical
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Long-Term Asthma Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Long-Term Asthma Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Long-Term Asthma Drugs Market Dynamics
  1. 2.1 Long-Term Asthma Drugs Industry Trends
  2. 2.2 Long-Term Asthma Drugs Industry Drivers
  3. 2.3 Long-Term Asthma Drugs Industry Opportunities and Challenges
  4. 2.4 Long-Term Asthma Drugs Industry Restraints
3 Long-Term Asthma Drugs Market by Company
  1. 3.1 Global Long-Term Asthma Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Long-Term Asthma Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Long-Term Asthma Drugs Company Ranking (2024-2026)
  4. 3.4 Global Long-Term Asthma Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Long-Term Asthma Drugs Company Product Type and Application
  6. 3.6 Global Long-Term Asthma Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Long-Term Asthma Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Long-Term Asthma Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Long-Term Asthma Drugs Market by Type
  1. 4.1 Long-Term Asthma Drugs Type Introduction
  2. 4.1.1 Tablet
  3. 4.1.2 Spray
  4. 4.2 Global Long-Term Asthma Drugs Sales Value by Type
  5. 4.2.1 Global Long-Term Asthma Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Long-Term Asthma Drugs Sales Value by Type (2021-2032)
  7. 4.2.3 Global Long-Term Asthma Drugs Sales Value Share by Type (2021-2032)
5 Long-Term Asthma Drugs Market by Application
  1. 5.1 Long-Term Asthma Drugs Application Introduction
  2. 5.1.1 Retail Pharmacy
  3. 5.1.2 Online Pharmacy
  4. 5.1.3 Hospital Pharmacy
  5. 5.2 Global Long-Term Asthma Drugs Sales Value by Application
  6. 5.2.1 Global Long-Term Asthma Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Long-Term Asthma Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Long-Term Asthma Drugs Sales Value Share by Application (2021-2032)
6 Long-Term Asthma Drugs Regional Value Analysis
  1. 6.1 Global Long-Term Asthma Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Long-Term Asthma Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Long-Term Asthma Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Long-Term Asthma Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Long-Term Asthma Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Long-Term Asthma Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Long-Term Asthma Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Long-Term Asthma Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Long-Term Asthma Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Long-Term Asthma Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Long-Term Asthma Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Long-Term Asthma Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Long-Term Asthma Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Long-Term Asthma Drugs Sales Value Share by Country, 2025 VS 2032
7 Long-Term Asthma Drugs Country-level Value Analysis
  1. 7.1 Global Long-Term Asthma Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Long-Term Asthma Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Long-Term Asthma Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Long-Term Asthma Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Long-Term Asthma Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Long-Term Asthma Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Long-Term Asthma Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Long-Term Asthma Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Long-Term Asthma Drugs Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Long-Term Asthma Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Long-Term Asthma Drugs Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Long-Term Asthma Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche Long-Term Asthma Drugs Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 Pfizer
  20. 8.4.1 Pfizer Company Information
  21. 8.4.2 Pfizer Business Overview
  22. 8.4.3 Pfizer Long-Term Asthma Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Pfizer Long-Term Asthma Drugs Product Portfolio
  24. 8.4.5 Pfizer Recent Developments
  25. 8.5 GlaxoSmithKline
  26. 8.5.1 GlaxoSmithKline Company Information
  27. 8.5.2 GlaxoSmithKline Business Overview
  28. 8.5.3 GlaxoSmithKline Long-Term Asthma Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 GlaxoSmithKline Long-Term Asthma Drugs Product Portfolio
  30. 8.5.5 GlaxoSmithKline Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Long-Term Asthma Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Long-Term Asthma Drugs Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 Vectura Group
  38. 8.7.1 Vectura Group Company Information
  39. 8.7.2 Vectura Group Business Overview
  40. 8.7.3 Vectura Group Long-Term Asthma Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Vectura Group Long-Term Asthma Drugs Product Portfolio
  42. 8.7.5 Vectura Group Recent Developments
  43. 8.8 Teva Pharmaceutical
  44. 8.8.1 Teva Pharmaceutical Company Information
  45. 8.8.2 Teva Pharmaceutical Business Overview
  46. 8.8.3 Teva Pharmaceutical Long-Term Asthma Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Teva Pharmaceutical Long-Term Asthma Drugs Product Portfolio
  48. 8.8.5 Teva Pharmaceutical Recent Developments
  49. 8.9 Boehringer Ingelheim
  50. 8.9.1 Boehringer Ingelheim Company Information
  51. 8.9.2 Boehringer Ingelheim Business Overview
  52. 8.9.3 Boehringer Ingelheim Long-Term Asthma Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Boehringer Ingelheim Long-Term Asthma Drugs Product Portfolio
  54. 8.9.5 Boehringer Ingelheim Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst